Fragmentomics is a wonderful concept in liquid biopsy. Similar to a muti-omics solution, fragmentomics looks at the composition of cf-DNA (length profile traditionally) to identify the ct-DNA profile. From here you can infer all sorts of useful information about the patients cancer. What makes it different from multi-omics is that you use the same DNA assay as for standard liquid biopsy. So twice the bang for a single buck! Seems like most ct-detection projects will soon be adding this to their arsenal. Up next, how to merge fragmentomics analysis with traditional variant calling? Im sure somebody's done it already...!
Susan Tousi, CEO of DELFI Diagnostics, joins Nasdaq to discuss how Delfi helps people live longer, healthier, cancer-free lives by detecting cancer early. Watch more: https://lnkd.in/e3KfEPEk
